tbuckley/cabot-search huggingface dataset:
Trastuzumab Deruxtecan With Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study
Authors: Erika Hamilton, Matthew D. Galsky, Sebastian Ochsenreither, Gianluca Del Conte, Miguel Martín, Maria José De Miguel, Evan Y. Yu, Anja Williams, Maria Gion, Antoinette R. Tan, Laila Agrawal, Annemie Rutten, Jean-Pascal Machiels, Sara Cresta, Philip R. Debruyne, Audrey Hennequin, Victor Moreno, Anna Minchom, Frances Valdes-Albini, Daniel Petrylak, Li Li, Zenta Tsuchihashi, Fumitaka Suto, Fu-Chih Cheng, Maha Kandil, Daniel Barrios, Sara Hurvitz
Journal: Clinical Cancer Research (2024)

Abstract Purpose: This multicenter phase Ib study investigated trastuzumab deruxtecan (T-DXd) plus nivolumab in patients with HER2-expressing metastatic breast cancer (mBC) and metastatic urothelial cancer (mUC). Patients and Methods: Part 1 determined the recommended dose for expansion of T-DXd plus nivolumab. Part 2 evaluated efficacy and safety; the primary endpoint was confirmed objective response rate by independent central review. Results: In part 1, seven patients with mBC were enrolled and received T-DXd 3.2 mg/kg (four patients) or 5.4 mg/kg (three patients) plus nivolumab. The recommended dose for expansion for T-DXd was 5.4 mg/kg plus nivolumab 360 mg intravenously every 3 weeks. In part 2, 32 patients with HER2-positive mBC (cohort 1; inclusive of three administered 5.4 mg/kg in part 1), 16 with HER2-low mBC (cohort 2), 30 with HER2-high mUC (cohort 3), and four with HER2-low mUC (cohort 4) were enrolled. At data cutoff (July 22, 2021), the confirmed objective response rates (95% confidence interval) for cohorts 1 to 4 were 65.6% (46.8%−81.4%), 50.0% (24.7%−75.3%), 36.7% (19.9%−56.1%), and not assessed due to small sample size, respectively. The median treatment duration (range) with T-DXd in cohorts 1 to 4 was 8.9 (1–23) months, 6.9 (1–21) months, 3.9 (1–21) months, and not assessed, respectively; the most common treatment-emergent adverse event was nausea (55.2%, 62.5%, 73.3%, and 75.0%, respectively). Adjudicated drug-related interstitial lung disease/pneumonitis rates (cohorts 1–3) were 20.7%, 0%, and 20.0%, respectively (one grade 5 each, cohorts 1 and 3). Conclusions: T-DXd plus nivolumab demonstrated promising antitumor activity in HER2-expressing mBC or mUC and safety consistent with the known profile of T-DXd. Interstitial lung disease/pneumonitis is an important risk and requires careful monitoring and prompt intervention.
EP.02F.01 Berberine and Osimertinib Inhibit Progression of EGFR-TKI Primary and Acquired Resistant NSCLC Cells by a Multimodal Intervention
Authors: D. Wu, C. Ding, M. Liu, Z. Zhao, W. Zhao, P. Chen, C. Chen, X. Zhang, Y. Li, J. Chen, H. Liu, Z. Hu
Journal: Journal of Thoracic Oncology (2024)
EP.02D.01 Macrophage Migration Inhibitory Factor Promotes Invasion and Epithelial to Mesenchymal Transition in Lung Adenocarcinoma
Authors: R.R. Hudlikar, H. Wang, S.K. Gara, M.R. Zhang, D.S. Schrump, S.R. Carr
Journal: Journal of Thoracic Oncology (2024)
EP.02B.01 PIK3C2A Potentiates Angiogenesis of Non-Small Cell Lung Cancer by Regulating ADRB2/VEGFA Signaling Pathway
Authors: T. Wang, H. Ge, S. Bu, X. Wang, C. Yang, X. Zheng, Y. Liu, X. Dong
Journal: Journal of Thoracic Oncology (2024)
EP.01D.06 Radon Exposure in Colombian Never-Smoker Non-Small Cell Lung Cancer Patients. A Pilot Study
Authors: W. Mantilla, A. Ruano-Ravina, M. Borras-Osorio, I. Munevar, L. Viola, J. Zuluaga, L. Rojas, A.F. Cardona, L.J. Tellez
Journal: Journal of Thoracic Oncology (2024)
EP.02B.04 Bioinformatics &amp; Machine Learning for Prognostic Model of LUSC by Identifying Programmed Cell Death Genes
Authors: S. Lu, L. Chen, K. Li, S. Liang, J. Xiong, H. Chen, Z. Wang, D. Yan, X. Nie, Y. Han, C. Xu, X. Leng
Journal: Journal of Thoracic Oncology (2024)
EP.02F.03 Elucidating the Role of XRCC6BP1 In Mitochondrial Bioenergetics and Metabolism in Non-Small Cell Lung Cancer
Authors: M.P. Barr, A. Woods, G. Kirwan, A. Heeran, A. Kilgallon, A. Raju, S. Cuffe, S. Finn
Journal: Journal of Thoracic Oncology (2024)
EP.02B.07 HFE as a Novel Gene Associated with Primary Lung Cancer Risk:A Mendelian Randomization and Bioinformatics Study
Authors: X. Liu, X. Qiu, X. Li, Q. Cai, L. Lin, L. Huang, R. Zeng, J. Li, H. Liu, J. He, W. Liang
Journal: Journal of Thoracic Oncology (2024)
EP.02C.01 Investigating the Role of VISTA Immune Checkpoint in Human and Murine Mesothelioma Cell Lines
Authors: A. Sehgal, B.A. Jacobson, H. Zhang, R.A. Kratzke, M. Patel, K. Lan, J. Lan, J. Allred
Journal: Journal of Thoracic Oncology (2024)
EP.01B.01 Geospatial Characterization of DNA Damage Repair (DDR) Mutations in Lung Cancer Patients in an Underserved Urban Population
Authors: J. Kao, M. Pasquinelli, R. Nguyen, A. Hulbert, A. Mallisetty, M.E. Wright, E. Abrol, F. Weinberg
Journal: Journal of Thoracic Oncology (2024)
P4.15E.01 Association Between Dynamic Patient-Reported Outcome-Based Symptom Exacerbation and Postoperative Complication in Lung Cancer
Authors: S. Huang, X. Zhou, C. Deng, H. Liu, Z. Li, X. Li, Y. Chen, D. Tang, Y. Tang, P.M.-K. Tang, Q. Shi, G. Qiao
Journal: Journal of Thoracic Oncology (2024)
P4.17C.01 Clinical Trial Enrollment at a Thoracic Oncology Program at a Single-Academic Institution Serving Primarily Underrepresented Patients
Authors: M. Pasquinelli, L. Liu, W. Ma, C. Zazueta, A. Guzman, M. Russell, C. Weldon, A. Salahudeen, R. Nguyen, F. Weinberg
Journal: Journal of Thoracic Oncology (2024)
P4.17F.02 Sociodemographic and Clinical Predictors of Diagnosis of Lung Cancer in the Emergency Department in a Large, Integrated Health System
Authors: M. Ragavan, M.J. Somers, M. Reed, A. Dang, M. Yang, T. Huang, D. Vinson, L. Sakoda, C. Triplett, R. Liu
Journal: Journal of Thoracic Oncology (2024)
EP.01A.05 Analysis of Diagnostic Delay and Its Impact on Survival in Lung Cancer Cases. Results from the Spanish Thoracic Tumor Registry
Authors: C. Candal-Pedreira, A. Ruano-Ravina, V. Calvo de Juan, M. Cobo, J.M. Trigo, D. Rodríguez-Abreu, A. Estival, E. Carcereny, M. Cucurull, R. López Castro, A. Medina, R. García Campelo, P. Cordeiro González, A. Sánchez-Gastaldo, J. Bosch-Barrera, B. Massutí, M. Dómine, C. Camps, A.L. Ortega, M. Provencio
Journal: Journal of Thoracic Oncology (2024)
P4.17D.06 Pan-Canadian Lung Cancer Observational Study (PALEOS): A Multicentre Ambispective Real-World Database Study in a Publicly Funded Health System
Authors: S. Kuruvilla, P. Wheatley-Price, F. Gwadry Sridhar, P. Joubert, O.I. Aseyev, L. Young, R. Sachdeva, B. Sheffield, M. Richardson, J. Bafaro, R. Seeger, A. Wojtyk, K. Bisson, A. Foo, G. Liu, P.K. Cheema
Journal: Journal of Thoracic Oncology (2024)
EP.01D.04 Impacts of Household Tobacco Smoke on Life-Long Non-Smoking Adults: An Internet-Based Population Survey in India
Authors: V. Brunelli, D.C. Currow, S. Chang, T. Buchanan, K. Reakes, S. Kochovska, L. Poulos, D. Ferreira, R. Iyer, S.K. Rajan
Journal: Journal of Thoracic Oncology (2024)
P4.17D.04 Insights into Lung Cancer During Pregnancy: Analysis of the National Inpatient Database (NIS)
Authors: N.A. Guevara Rodriguez, E. Perez, V. Chapiolkina, M. Ghimire, P. Budhathoki, S. Poudel, C. Olazagasti, N. Florez
Journal: Journal of Thoracic Oncology (2024)
EP.01C.01 Evolution of Lung Cancer Mortality Rates in Brazil (1996-2022)
Authors: J. Rey Brandariz, B. Wanderlei-Flores, C. Guerra-Tort, C. Candal Pedreira, G. García, A. Ruano-Ravina, L. Martín-Gisbert, L. Varela-Lema, M. Pérez-Ríos
Journal: Journal of Thoracic Oncology (2024)
P4.17E.01 Navigating from Target to Treatment: Early Impact of the Lung Precision Oncology Navigation Program (LPOP)
Authors: N. Ghazali, M. Ku, L. Corke, G. Liu, P. Bradbury, F. Shepherd, A. Sacher, L. Eng, L. Le, A. Ramsey, P. Sabatini, P. Pal, J. Schwock, M. Rabey, N. Leighl
Journal: Journal of Thoracic Oncology (2024)
EP.01A.01 Role of Diet and Exercise in Young Lung Cancer Patients with Driver Mutations (NCT04640259)
Authors: A. Wu, M. Bittoni, A.M. Harper, N. Florez, C.A. Granville, R. Erwin, B.J. Addario, D.P. Carbone, B.J. Gitlitz, J. Nieva
Journal: Journal of Thoracic Oncology (2024)
P4.15D.04 Association Between Emotional Distress and Immunotherapy Response in Advanced NSCLC (STRESS-LUNG-1): Biomarkers Exploratory Analyses
Authors: F. Wu, Y. Zeng, J. Zhou, Z. Qiu, C. Deng, F. Ma, C. Xia, A. Liang, Y. Peng, S. Wang, S. Yao, J. Liu, Y. Zhang, X. Zhang, X. Wang, X. Liu, C. Hu
Journal: Journal of Thoracic Oncology (2024)
P4.14C.07 A Combination of Routine and Novel Immunohistochemical Markers to Improve the Histological Diagnosis of Mesothelioma in Challenging Biopsies
Authors: P. Viola, H. Kudo, G. Valentine, J. Vidak, G. Srilal, S. Desai, N. Gupta, J. Nandi, M. Al-Sahaf, A. Mani
Journal: Journal of Thoracic Oncology (2024)
P4.15D.02 Risk of Osteoporosis and Bone Fracture by Systemic Therapy in Lung Cancer Survivors
Authors: M.L. Hsu, I. Trinh, J.A. Perez, E. Harper, L. Chiec, D.S. Bruno, G. Dutcher, M. Mirsky, A. Dowlati, Q. Wang
Journal: Journal of Thoracic Oncology (2024)
P4.15E.02 Acceptability and Feasibility of Integrating A Chatbot into Routine Lung Cancer Care: Patient and Clinician Perspectives
Authors: J. Wainwright, H. Toneff, J. Kalman, M. Mengesha, A. Strazinsky, W. Song, S. Beucker, E.P. Wileyto, C. Johnston, C. Cambareri, D. Yarosh, A. Blauch, D. Pucci, L.A. Jacobs, J.E. Bekelman, S.E. Kimmel, L.N. Shulman, S. Takvorian, K. Rendle
Journal: Journal of Thoracic Oncology (2024)
P3.06D.09 Reciprocal DNA Fusions and their Association with DNA Damage Response Genes in Patients with NSCLC Through cfDNA NGS
Authors: L.C. Roisman, R. Gillis, S. Jain, A. Anoze, W. Kian, D. Levitas, R. Grinber, T. Ben Shitrit, L. Soussan-Gutman, S. Olsen, N. Peled
Journal: Journal of Thoracic Oncology (2024)
P3.06D.08 ctDNA-NGS Assay (Liquid Biopsy) for Non-Small Cell Lung Cancer: Utility of Plasma Cell-Free DNA and Tissue NGS in Detecting Genetic Mutations
Authors: A. Papadakis, G. Kasymjanova, A. Spatz, V. Cohen, C. Pepe, L. Sakr, R. Merza, J. Agulnik
Journal: Journal of Thoracic Oncology (2024)
P3.06E.02 Serum NY-ESO-1 And XAGE1 Antibodies Are Diagnostic and Cancer-Specific Immunomonitoring Markers in NSCLC
Authors: M. Oka, K. Kurose, Y. Nojima, S. Saisho, K. Shimizu, M. Nakata, T. Oga
Journal: Journal of Thoracic Oncology (2024)
P3.06D.14 Liquid Biopsy-Based Single T-Cell Dynamic Polyfunctionality Profiling as a NSCLC Immunotherapy Biomarker
Authors: Z.-F. Lim, X. Wu, L. Zhu, H. Albandar, M. Hafez, C. Zhao, M. Almubarak, M. Smolkin, H. Zheng, S. Wen, P.C. Ma
Journal: Journal of Thoracic Oncology (2024)
P3.02G.04 JP11646-mediated PIM2 Inhibition Has Potent Antitumor Effects in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung
Authors: K. Minton, P.D. Pham, M. Opyrchal, K.P. Lee, M.D. Shields
Journal: Journal of Thoracic Oncology (2024)
P3.03I.18 Optimizing Delivery of Anti-Cancer Therapeutics in Lung Adenocarcinoma Using Ultrasound-Induced Cavitation of Microbubbles
Authors: R. Hoshi, K. Joshi, R. Sanwal, M. Lodyga, E. Hysi, A. Lau, Y.F. Wu, W. Lee, K. Thu
Journal: Journal of Thoracic Oncology (2024)
P3.06D.06 Incremental Value of Liquid Biopsy in the Initial Evaluation of Non-Small Cell Lung Cancer Patients Undergoing Tissue Based Molecular Testing
Authors: B.A. Bleiberg, D.G. Scholes, D.A. Dravid, L.L. Sun, A.P. Singh, R.B. Cohen, C.J. Langer, M.E. Marmarelis, C. Aggarwal
Journal: Journal of Thoracic Oncology (2024)
P3.06F.05 Spatial Profiling of the Tumor Microenvironment of SMARCA4-Mutant NSCLCs Using Whole-Slide Multiplex Fluorescence Imaging
Authors: A. Gagné, J.-R. Lin, S. Santagata, S.R. Talemi, M. Mino-Kenudson, M. Trovero, M. Paschini, L.V. Sequist, J. Luo, A.J. Iafrate, C. Kim, D.A. Barbie, L.M. Sholl, I. Dagogo-Jack, P.K. Sorger
Journal: Journal of Thoracic Oncology (2024)
P3.06E.06 Angiogenesis and Immune-Related Biomarkers in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Authors: D. Grapsa, A. Papadopoulou, E. Kokkotou, S. Gaitanakis, I. Gkiozos, A. Charpidou, K. Syrigos
Journal: Journal of Thoracic Oncology (2024)
P3.06D.03 Prognostic and Predictive ctDNA Signature for Patients on Targeted Therapy for Metastatic NSCLC: A Pathway-based Approach
Authors: Z. Raza, J. Zhang, X. Le, J.V. Heymach, H.T. Tran, S. Heeke, J. Bronk, M.S. Ning, S. Gandhi, A. Chen, J.W. Welsh, Q.-N. Nguyen, M.S. O’Reilly, J.Y. Chang, Z. Liao, S.H. Lin, D.C. Qian
Journal: Journal of Thoracic Oncology (2024)
P2.14A.08 Tyrosine Kinase Inhibitors (Alone or in Combination) for the Management of Advanced Thymic Epithelial Tumors (TETs) Among Hispanics
Authors: V.C.C. de Lima, H. Freitas, J.D. Flórez, A. Ruíz-Patiño, A.F. Cardona, S. Mejía, L. Rojas, J. Zuluaga, L. Corrales, C. Martín, L. Mas, R. Motta, L. Viola, S. Martínez, C. Carvajal, N. Wagner-Gutierrez, N. Sánchez, L.E. Pino, L. Raez, C. Rolfo, O. Arrieta
Journal: Journal of Thoracic Oncology (2024)
P3.03H.04 Molecular and Clonal Evolution of Primary Lesions vs Brain Metastasis and Progressive Disease of EGFR Mutated Patients
Authors: A. Ruiz-Patiño, O. Arrieta, L. Rojas, J. Zuluaga, C. Martin, L. Corrales, L. Viola, J. Rodriguez, H. Carranza, C. Vargas, J. Otero, A.F. Cardona
Journal: Journal of Thoracic Oncology (2024)
P3.06F.06 Spatial Transcriptomic Profiling Reveals Molecular Patterns Associated with Poor Prognosis in ALK-Rearranged NSCLC Patients
Authors: W. Khatoon, A. Nambirajan, P.S. Malik, S. Vasant, K. yadav, A. Katiyar, D. Jain
Journal: Journal of Thoracic Oncology (2024)
P3.06E.01 Evaluation of the Immune Landscape of Patients with Adenosquamous NSCLC (LUAS)
Authors: M. Lee, T. Adeyelu, S. Wang, A. Elliott, A. Vanderwalde, L. Villaruz, H. Khan, B. Herzberg, S.Y. Kim, P. Ma, S. Liu, B. Halmos, H. Cheng
Journal: Journal of Thoracic Oncology (2024)
P3.01E.01 Real-World Analysis of GLP-1 Receptor Agonists and Lung Cancer Risk in Treatment-Naïve Type 2 Diabetes: Potential Impact of Obesity and Gender
Authors: J. Song, A.E. Cali Daylan, K.-Y. Chi, Y. Chang, R.S. Memon, J. Lee, J. Ahn, C.-H. Chiang, H. Cheng
Journal: Journal of Thoracic Oncology (2024)
P3.03I.05 DSTYK Inhibition as a Novel Strategy for Taxane-Based Chemotherapy Sensitation in Early and Advanced Lung Cancer
Authors: M. Echepare, B. Picabea, A. Arricibita, A. Teijeira, A. Pasquier, C. Zandueta, E. Santamaría, J. Fernández-Irigoyen, O. Romero, M. Sánchez-Céspedes, F. Lecanda, J. Hernández, E. Felip, A. Cruz, M. Provencio, L.M. Montuenga, K. Valencia
Journal: Journal of Thoracic Oncology (2024)
P3.06F.03 Unbiased Proteomics and Multi-Omics Discovery of a Peripheral Blood-Based Classifier for Early Lung Cancer Detection
Authors: B. Koh, M. Liu, L. Yarmus, J. Choi, E. Khaledian, P. Ranjan, G. Shu, D. Vitko, R.J.X. Zawada, J.Y. Zeng, J. Yee, B. Wilcox, C. Belthangady, P. Ma
Journal: Journal of Thoracic Oncology (2024)
P3.06D.04 Role of ctDNA Variant Allele Frequency in Predicting Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Authors: R. Paredes de la Fuente, A. Peleg, S. Litchman, J. Gomez, D. Doroshow, F. Hirsch, R. Veluswamy, T. Marron, C. Smith, N. Rohs, C. Rolfo
Journal: Journal of Thoracic Oncology (2024)
P3.03H.03 Feasibility of Metastatic Lymph Node-informed ctDNA Analysis in Surgically Resected NSCLC Patients
Authors: S. Ohara, K. Suda, E. Kalashnikova, A. Hamada, M. Chiba, M. Shimoji, T. Takemoto, S. Sudhaman, S.K. Cheung, M. Krainock, J. Feeney, H. Sethi, M.C. Liu, J. Soh, Y. Tsutani, T. Mitsudomi
Journal: Journal of Thoracic Oncology (2024)
P3.02F.06 Multi-Omics Reveals Effects of Gut Microbiome on Tumor Immune and Metabolism in Mouse Lewis Lung Carcinoma Model
Authors: Z. Hu, R. Shi, F. Mao, Z. Zhang, Y. Wang, B. Li, H. Zhang, Y. Li, H. Liu, J. Chen
Journal: Journal of Thoracic Oncology (2024)
P3.03I.15 The Mechanisms and Impact of EGFR TKIs in Modulating Blood Immune Cells in Patients with Oncogene-Driven NSCLC
Authors: T. Li, W. Ma, S. Chen, D. Montoya, V.M. Viswanath, I.C. Zhao, A.P. Steele
Journal: Journal of Thoracic Oncology (2024)
P3.03I.01 Targeting RLIP76 with a Novel Small Molecule for Lung Cancer Therapy
Authors: S.R. Ghafouri, R. Horn, A. Kamat, J. Sekhon, D. Pawar, S. Shahrokh, L. Tijani, M. Melkus, S. Singh
Journal: Journal of Thoracic Oncology (2024)
P3.03I.11 The ATXN3-USP25-TRMT1 Axis Regulates tRNAm2,2G Modification and Promotes Osimertinib Resistance in Lung Cancer
Authors: T. Chu, J. Li, K. Huang, S. Pan, H. Lu, J. Qian, Y. Wu
Journal: Journal of Thoracic Oncology (2024)
P3.06D.10 Concordance of Liquid Biopsy and Tissue Biopsy for the Detection of EGFR Mutation in Stage III NSCLC in the United States
Authors: U. Malapelle, F. Nasirova, A. Wang, M. Cooper, R. Salomonsen, E. Baser, E.-A. Raiber-Moreau, C. Ortiz-Villalón, Y. Chuang, Y.J. Kim
Journal: Journal of Thoracic Oncology (2024)
P3.03I.04 Annamycin: Opening New Doors for Organotropic Targeting of Primary and Metastatic Lung Cancer
Authors: R. Zielinski, K. Grela, S. Peng, R. Cardenas-Zuniga, S. Skora, I. Fokt, W. Dempke, W. Priebe
Journal: Journal of Thoracic Oncology (2024)
P3.01D.03 Evaluating Lung Cancer Disparities Among Transgender Populations: A Retrospective Cohort Analysis
Authors: T. Tabernacki, A. Thakur, R. Amkraut, M.A. Maravillas, S. Gupta, S. Banik, M. McNamara, K. Mishra
Journal: Journal of Thoracic Oncology (2024)
P2.17A.02 Cost-Efficiency Modeling of Conversion to Biosimilar Bevacizumab-bvzr in Metastatic Non-Small Cell Lung Cancer in Medicare
Authors: J.A. Roth, D. Kratochvil, S. Dorman, J.M. Kelton, M. Bernauer
Journal: Journal of Thoracic Oncology (2024)
P3.01D.05 Gender Differences in Lung Cancer Incidence Among Patients Who Never Smoked Cigarettes: A Systematic Literature Review
Authors: D. Molena, C. Aggarwal, N. Florez, S. Peters, J. Brahmer, E. Shum, R. Salomonsen, J. Chaieb, M. Chau, R. Shenolikar, L. Luciani-Silverman, D. Guy, L. Woldmann, A.-A. Ciritel, H. Wakelee
Journal: Journal of Thoracic Oncology (2024)
P2.17A.06 Impact of COVID-19 Diagnosis and Treatment for Lung Cancer in the US National Cancer Database (NCDB) from 2014 To 2021
Authors: I. Emmerick, A. Crawford, M. Epstein, A. Markel, L. Suh, C. Gray, M. Maxfield, C. Berg, K. Uy, F. Lou
Journal: Journal of Thoracic Oncology (2024)
P2.16A.02 Improving Patients' Awareness of Biomarker Test Timing and Purpose with 4R Oncology Intervention
Authors: F. Weinberg, N. Martin, J. Trosman, N. Mohindra, M. Pasquinelli, L. Feldman, R. Nguyen, C. Chan, J. Feliciano, R. Sacks, M.S. Weinfeld, W. Waugh, J. Martin, J. Woodyard, A. Rediske, P. Khosla, T. Lycan, A. Ravelo, A. Lile, C.B. Weldon
Journal: Journal of Thoracic Oncology (2024)
P2.14B.02 Application of Chemokine Receptor 4 Targeted 68Ga Pentixafor in Evaluation of Thymic Epithelial Tumors (TETs): A Prospective Study
Authors: X. Gao, R. Wang, X. Peng, X. Zhou, C. Guo, S. Li, Z. Zhu, Y. Chen
Journal: Journal of Thoracic Oncology (2024)
P3.02G.02 Integrin-Linked Kinase Facilitates Drug Tolerant Persister Cell Survival and EMT in Response to EGFR Targeted Therapy
Authors: R. Shi, D. Farnsworth, T. Atwal, J. Chow, R. Sheena, C.-M. Lee, Y. Inoue, S. Awrey, P. McDonald, R. Somwar, M. Ladanyi, S. Dedhar, K. Bennewith, W. Lockwood
Journal: Journal of Thoracic Oncology (2024)
P2.14B.05 eVOLVE-Meso: A Global Phase 3 Study of First-Line Volrustomig Plus Chemotherapy in Unresectable Pleural Mesothelioma
Authors: A. Scherpereel, D.A. Fennell, N. Fujimoto, M.E. Marmarelis, A. Tsao, J. Aerts, X. Li, T. Dalvi, H. Jiang, L. Krug, M. Zauderer
Journal: Journal of Thoracic Oncology (2024)
P2.16E.01 Lung Cancer Patients' Support Preferences: Insights from a Global Patient Experience Survey
Authors: K. Clayton, M. Daniels, J. Fox, B. Gaspar, M. Hennink, J. Mayans, A. McNamara, L. Pretorius, M. Rigney, M. Dohr
Journal: Journal of Thoracic Oncology (2024)
P3.03I.06 Neoadjuvant Gefitinib in EGFR Mutated NSCLC (a Phase 2 Window-Of-Opportunity Study): Deep Genomic and Transcriptomic Analysis
Authors: A.C. Tan, J.-C. Yeo, M. Pang, J.J.S. Alvarez, A.Y. Guo, R. Hoo, A. Takano, B.-H. Ong, J. Yeong, Z. Wu, J. Yuan, S. S, N.L. Sim, K.P. Chua, W.L. Tam, L. Wang, D.P.X. Lau, S.P.L. Saw, A. Jain, G.G.Y. Lai, W.L. Tan, M.-K. Ang, Q.S. Ng, R. Kanesvaran, W.T. Lim, A.J. Skanderup, D.S.W. Tan
Journal: Journal of Thoracic Oncology (2024)
P2.14A.14 A Real-World Multicenter Retrospective Study of Treatment Outcomes with Ipilimumab and Nivolumab in Mesothelioma
Authors: A. Sridhar, A. Schwecke, S. Durer, M.L. Hsu, A. Singh, A.S. Mansfield, Y. Lou, J.R. Molina, K. Leventakos, A. Dimou, R. Manochakian, M. Shanshal, V. Ernani, J.N. Moffett, A. Luce, K. Parikh
Journal: Journal of Thoracic Oncology (2024)
P2.11A.11 Impact of Proton Pump Inhibitor Use on Faecal Microbiome in Patients with NSCLC Treated with Immune Checkpoint Inhibitor
Authors: Y. Huang, J. Lee, C.K. Sim, J.J. Zhao, K. Sooi, A. Wong, S.H. Tay, Y.Y. Soon, F. Aminkeng, B.C. Goh, D.S. Tan, R.A. Soo
Journal: Journal of Thoracic Oncology (2024)
P2.11C.03 Immune-Related Adverse Events are Associated with Survival in Chinese Lung Cancer Patients Treated With Immunotherapy
Authors: Y. Zhang, H. Yan, L. Zeng, G. Zhou, Y. Wu, H. Qin, N. Yang, Z. Huang, D. Yang, X. Zhang, Y. Zhang, K. Graham-Siegenthaler, R. Walls, S. Hamzic, Y. He, R. Mohindra, S. Chandler, Z. Li, R. Luo, A. Saha, C. Hammer
Journal: Journal of Thoracic Oncology (2024)
P2.16A.01 Actionable Alterations Identification in NSCLC by Comprehensive Genomic Profiling for Clinical Trial Enrollment: EPROPA
Authors: S. Vallone, F. Passiglia, A. Listi, P. Bironzo, A. Merlini, F. Benso, F. Napoli, F.A. Barbu, V. Zambelli, F. Tabbò, M.L. Reale, C. Sini, E. Roca, P.A. Taveggia, F. Simionato, L. Buffoni, L. Mazilu, V. Barbieri, D. Pignataro, A. Araujo, L. Paz-Ares, E. Félip, N. Secen, A. Comanescu, K. Mati Ramizi, A.C. Bettini, V. Scotti, H. Linardou, K. Mohorcic, G. Meoni, M. Volante, G. Scagliotti, U. Malapelle, L. Righi, S. Novello
Journal: Journal of Thoracic Oncology (2024)
P2.16F.01 Patient-Led Oncogene-Driven Lung Cancer Translational Research to Expedite Therapeutic Development
Authors: M.A. Muskavitch, R.B. Hall, J. Lowy, E. Gefroh, E.S. Venanzi, J. Noonan, K. Li, K.W. Culver
Journal: Journal of Thoracic Oncology (2024)
P2.14A.13 Discovery and Clinical Application of Potential Prognostic Genes for Clinical Outcome in Malignant Pleural Mesothelioma
Authors: T. Kato, S. Okado, H. Huang, Y. Imamura, Y. Nomata, H. Watanabe, Y. Kawasumi, Y. Kadomatsu, H. Ueno, S. Nakamura, T. Mizuno, T.F. Chen-Yoshikawa
Journal: Journal of Thoracic Oncology (2024)
P2.14A.04 Mapping the Distribution of Ectopic Thymus Through Flow Cytometry Analysis of CD3mediumTCRvßmediumCD4+CD8+ T Cells
Authors: Y. Ao, J. Gao, J-h. Jiang, S. Wang, C. Jin, H. Wang, J. Ding
Journal: Journal of Thoracic Oncology (2024)
P2.14A.03 Prediction of Post-Surgical Recurrence of Thymic Epithelial Tumours Using Clinicopathological Parameters Incorporating TNM9 Classification
Authors: Y.Z. Zhang, A. Rice, K. Wassilew, C. Brambilla, J.L. Robertus, L. D'Sa, E. Lim, S. Begum, S. Buderi, S. Jordan, V. Anikin, J. Finch, N. Asadi, E. Beddow, J.L. Garner, J. Morjaria, R. Lee, F. McDonald, N. Tokaca, G. Antoniou, C.A. Ridge, S.P. Padley, P. Dalal, P.L. Shah, A. Devaraj, S. Popat, A.G. Nicholson
Journal: Journal of Thoracic Oncology (2024)
P4.11E.15 Risk Factors for Ir-AEs in Patients with NSCLC Receiving Chemotherapy Combined with a PD-1/PD-L1 Inhibitor or Nivolumab and Ipilimumab
Authors: A. Nomura, T. Masuda, S. Takao, Y. Izumi, Y. Araki, Y. Takayama, K. Masuda, K. Yamaguchi, S. Sakamoto, Y. Horimasu, T. Nakashima, H. Iwamoto, T. Senoo, H. Shoda, N. Ishikawa, M. Yamasaki, H. Hamada, M. Okada, N. Hattori
Journal: Journal of Thoracic Oncology (2024)
P4.11E.08 Integrated PK/PD Modeling for Uliledlimab, an Anti-CD73 Monoclonal Antibody, In Non-Small Cell Lung Cancer Patients
Authors: J. Yanez, V. Wang, M. Khalil, Y. Zhang, Y. Li, C. Xu, J.-K. Chung
Journal: Journal of Thoracic Oncology (2024)
P4.11E.14 Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated with PD-1/PD-L1 Inhibitors
Authors: L. Wu, H. Wang, y. kong, j. li, l. xu, q. wang, x. pu, y. zhou, k. li
Journal: Journal of Thoracic Oncology (2024)